| Aug 15 |
Bristol Myers, Novartis react as Medicare prices for key drugs announced
|
| Aug 15 |
Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?
|
| Aug 15 |
Medicare to save $6B in 2026 from the first ever Part D drug pricing negotiations
|
| Aug 13 |
US judge denies initial attempt by Novartis to block generic Entresto launch
|
| Aug 13 |
Update: Novartis Unable to Block Launch of MSN Pharmaceuticals' Version of Entresto, Court Decision Shows
|
| Aug 12 |
Fed court rules against Novartis in generic Entresto case: report
|
| Aug 9 |
Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal & Other Updates
|
| Aug 8 |
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease
|
| Aug 8 |
US FDA approves Novartis’ Fabhalta in IgAN treatment
|
| Aug 7 |
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
|
